Akcea and Ionis Announce Initiation of NEURO-TTRansform Phase 3 Clinical Trial for AKCEA-TTR-LRx in Patients with Polyneuropathy Driven by Hereditary TTR AmyloidosisGlobeNewsWire • 11/25/19
Akcea and Ionis Announce Closing of Licensing Agreement with Pfizer Inc. for Investigative Antisense Therapy AKCEA-ANGPTL3-L(Rx)GlobeNewsWire • 11/19/19
Akcea Therapeutics, Inc. (AKCA) CEO Damien McDevitt on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/06/19
Akcea Therapeutics (AKCA) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/05/19
How A Deal With Pfizer Sent This Pharma Stock Rocketing In High VolumeInvestors Business Daily • 10/07/19
Akcea and Pfizer Inc. Announce Licensing Agreement for investigative antisense therapy AKCEA-ANGPTL3-L(Rx)GlobeNewsWire • 10/07/19
Positive Phase 1 Results of AKCEA-TTR-LRx Presented at the Heart Failure Society of America Annual MeetingGlobeNewsWire • 09/16/19
Akcea Therapeutics, Inc. (AKCA) CEO Paula Soteropoulos on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/07/19
Akcea Therapeutics, Inc. (AKCA) CEO Paula Soteropoulos on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/09/19
Akcea Therapeutics (AKCA) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 05/01/19
Akcea Therapeutics (AKCA) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/25/19